This company has been marked as potentially delisted and may not be actively trading. Cerecor (CERC) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock CERC vs. TVTX, LQDA, JANX, EVO, GPCR, SPRY, MNKD, DYN, VERA, and ANIPShould you be buying Cerecor stock or one of its competitors? The main competitors of Cerecor include Travere Therapeutics (TVTX), Liquidia (LQDA), Janux Therapeutics (JANX), Evotec (EVO), Structure Therapeutics (GPCR), ARS Pharmaceuticals (SPRY), MannKind (MNKD), Dyne Therapeutics (DYN), Vera Therapeutics (VERA), and ANI Pharmaceuticals (ANIP). These companies are all part of the "medical" sector. Cerecor vs. Travere Therapeutics Liquidia Janux Therapeutics Evotec Structure Therapeutics ARS Pharmaceuticals MannKind Dyne Therapeutics Vera Therapeutics ANI Pharmaceuticals Travere Therapeutics (NASDAQ:TVTX) and Cerecor (NASDAQ:CERC) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their media sentiment, valuation, community ranking, analyst recommendations, profitability, risk, earnings, dividends and institutional ownership. Which has better earnings and valuation, TVTX or CERC? Cerecor has lower revenue, but higher earnings than Travere Therapeutics. Cerecor is trading at a lower price-to-earnings ratio than Travere Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTravere Therapeutics$273.53M5.14-$111.40M-$2.81-5.64Cerecor$6.70M56.03-$63.50M-$0.57-6.86 Do insiders and institutionals believe in TVTX or CERC? 62.8% of Cerecor shares are owned by institutional investors. 4.2% of Travere Therapeutics shares are owned by company insiders. Comparatively, 45.7% of Cerecor shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Do analysts recommend TVTX or CERC? Travere Therapeutics currently has a consensus target price of $31.79, indicating a potential upside of 100.67%. Given Travere Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Travere Therapeutics is more favorable than Cerecor.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Travere Therapeutics 0 Sell rating(s) 2 Hold rating(s) 13 Buy rating(s) 0 Strong Buy rating(s) 2.87Cerecor 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the media favor TVTX or CERC? In the previous week, Travere Therapeutics had 9 more articles in the media than Cerecor. MarketBeat recorded 9 mentions for Travere Therapeutics and 0 mentions for Cerecor. Travere Therapeutics' average media sentiment score of 0.85 beat Cerecor's score of 0.16 indicating that Travere Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Travere Therapeutics Positive Cerecor Neutral Which has more volatility and risk, TVTX or CERC? Travere Therapeutics has a beta of 0.88, meaning that its stock price is 12% less volatile than the S&P 500. Comparatively, Cerecor has a beta of 1.44, meaning that its stock price is 44% more volatile than the S&P 500. Does the MarketBeat Community favor TVTX or CERC? Cerecor received 91 more outperform votes than Travere Therapeutics when rated by MarketBeat users. Likewise, 74.00% of users gave Cerecor an outperform vote while only 61.44% of users gave Travere Therapeutics an outperform vote. CompanyUnderperformOutperformTravere TherapeuticsOutperform Votes9461.44% Underperform Votes5938.56% CerecorOutperform Votes18574.00% Underperform Votes6526.00% Is TVTX or CERC more profitable? Travere Therapeutics has a net margin of -137.90% compared to Cerecor's net margin of -1,194.82%. Cerecor's return on equity of -261.82% beat Travere Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Travere Therapeutics-137.90% -1,636.87% -55.95% Cerecor -1,194.82%-261.82%-133.96% SummaryTravere Therapeutics and Cerecor tied by winning 9 of the 18 factors compared between the two stocks. Get Cerecor News Delivered to You Automatically Sign up to receive the latest news and ratings for CERC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CERC vs. The Competition Export to ExcelMetricCerecorPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$375.40M$6.47B$5.33B$8.31BDividend YieldN/A2.64%5.20%4.10%P/E Ratio-6.868.4026.7219.60Price / Sales56.03258.84395.56117.96Price / CashN/A65.8538.3234.62Price / Book17.776.416.764.50Net Income-$63.50M$143.73M$3.23B$248.40M Cerecor Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CERCCerecorN/A$3.91+3.2%N/A-65.3%$375.40M$6.70M-6.8631TVTXTravere Therapeutics2.9559 of 5 stars$17.26+1.5%$31.79+84.2%+139.3%$1.53B$273.53M-4.20460LQDALiquidia3.4555 of 5 stars$17.12+0.5%$25.56+49.3%+18.5%$1.46B$14.14M-10.5050News CoverageAnalyst ForecastTrading HaltedJANXJanux Therapeutics2.7554 of 5 stars$24.36+0.8%$95.25+291.1%-44.4%$1.44B$9.34M-20.7730Positive NewsEVOEvotec1.4848 of 5 stars$4.04+1.6%$5.93+47.0%-22.1%$1.43B$788.22M0.004,200Positive NewsGap UpGPCRStructure Therapeutics2.1431 of 5 stars$24.48-2.1%$78.00+218.7%-32.2%$1.40BN/A-32.91136SPRYARS Pharmaceuticals2.3849 of 5 stars$14.07-1.4%$31.00+120.4%+62.6%$1.38B$89.15M-27.5890News CoverageAnalyst DowngradeInsider TradeMNKDMannKind2.9726 of 5 stars$4.42-1.2%$10.00+126.5%-12.4%$1.34B$297.60M63.07400DYNDyne Therapeutics3.4848 of 5 stars$11.75+0.8%$47.25+302.1%-62.3%$1.33BN/A-3.29100Positive NewsGap DownVERAVera Therapeutics3.3569 of 5 stars$20.82-0.9%$63.33+204.2%-48.3%$1.33BN/A-7.9840Positive NewsANIPANI Pharmaceuticals4.8152 of 5 stars$60.50+0.6%$80.13+32.4%-7.1%$1.31B$674.07M-109.27600Positive News Related Companies and Tools Related Companies Travere Therapeutics Alternatives Liquidia Alternatives Janux Therapeutics Alternatives Evotec Alternatives Structure Therapeutics Alternatives ARS Pharmaceuticals Alternatives MannKind Alternatives Dyne Therapeutics Alternatives Vera Therapeutics Alternatives ANI Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CERC) was last updated on 5/23/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | SponsoredSilver Is the New Oil—And the World’s Running DryElon's Next Market Move Could Send Silver Soaring Every industry Elon Musk touches explodes—from Tesla to S...Priority Gold | SponsoredTrump’s Bitcoin Reserve is No Accident…Bitcoin's supply is being drained at unprecedented rates, but while most investors focus solely on Bitcoin, th...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cerecor Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cerecor With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
